David J. Diemert

Jan 16, 2025 | nature.com | Bo Zhang |Shiyu Chen |Nadine Rouphael |Angela R. Branche |David J. Diemert |Daniel S. Graciaa | +15 more

AbstractNeutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance.

Mar 18, 2024 | thelancet.com | Jeannot F. Zinsou |Institut für Tropenmedizin |Universität Tübingen |David J. Diemert

Summary A human hookworm vaccine is being developed to protect children against iron deficiency and anaemia associated with chronic infection with hookworms. Necator americanus aspartic protease-1 (Na-APR-1) and N americanus glutathione S-transferase-1 (Na-GST-1) are components of the blood digestion pathway critical to hookworm survival in the host.

Aug 28, 2023 | nature.com | Angela R. Branche |David J. Diemert |Susan J Little |Evan Anderson |Angelica C. Kottkamp |Anne F. Luetkemeyer | +19 more

AbstractVaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of a second boost with monovalent or bivalent variant vaccines from mRNA and protein-based platforms targeting wild-type, Beta, Delta and Omicron BA.1 spike antigens.